REGENERON PHARMAC.DL-,001
REGENERON PHARMAC.DL-,001/ US75886F1075 /
RGO
|
10/05/2024 08:03:19
|
Chg.
+12.40
|
Volume |
Bid20:59:44 |
Demandez à20:59:44 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
|
897.20EUR
|
+1.40%
|
0
Chiffrre d'affaires: 0.00 |
-Bid taille: - |
-Ask la taille: - |
99.59 Mrd.EUR |
- |
- |
Description de l'entreprise
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.
Conseil d'administration & Conseil de surveillance
| PDG |
| Dr. Leonard S. Schleifer |
| Conseil d'administration |
| Robert E. Landry, Dr. George D. Yancopoulos |
| Conseil de surveillance |
| Arthur F. Ryan, Christine A. Poon, Craig B. Thompson, Dr. Bonnie L. Bassler, Dr. George D. Yancopoulos, Dr. Leonard S. Schleifer, Dr. Marc Tessier-Lavigne, George L. Sing, Huda Y. Zoghbi, M.D., Joseph L. Goldstein, M.D., Michael S. Brown, M.D., Tony Coles, M.D. |
Données de l'entreprise
| Nom: |
Regeneron Pharmaceuticals Inc. |
| Adresse: |
777 Old Saw Mill River Road,Tarrytown, New York 10591-6707, USA |
| Téléphone: |
+1-914-847-7000 |
| Fax: |
- |
| Courriel: |
-
|
| Internet: |
is.gd/sEAmh8 |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
68.40% |
| IPO date: |
12/04/1991 |
Relations avec les investisseurs
| Nom: |
- |
| Téléphone IR: |
+1-914-847-7741 |
| IR-Fax: |
- |
| E-mail IR: |
invest@regeneron.com
|
